Therapeutic options for treatment of Merkel cell carcinoma.
Merkel cell carcinoma (MCC) is a rare malignant neuroendocrine carcinoma of the skin. Owing to the aggressiveness of this tumor and the bad overall survival, we reviewed the therapeutic strategies, including surgery, radiation, and chemotherapy to find out the potentially best treatment option for one patient treated at our hospital. In addition, we investigated MCC biopsies using the FLAVINO assay to find out if individual chemoresponse testing might be a useful supplement in decision-making for the optimal therapeutic option for our MCC patient. The different results achieved using cisplatin, docetaxel, and cetuximab led to the conclusion that an individual chemoresponse testing in a predictive short-time assay might potentially be a useful diagnostic tool in identifying potentially effective chemotherapy treatments.
Gessner
Kathrin
K
Department of Otolaryngology-Head and Neck Surgery, University of Leipzig, Liebigstrasse 10-14, 04103 Leipzig, Germany. kathrinnora.gessner@medizin.uni-leipzig.de
Wichmann
Gunnar
G
Boehm
Andreas
A
Reiche
Anett
A
Bertolini
Julia
J
Brus
Johannes
J
Sterker
Ina
I
Dietzsch
Stefan
S
Dietz
Andreas
A
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D015266:Carcinoma, Merkel Cell / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D002945:Cisplatin / Q000627:therapeutic use*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008875:Middle Aged; D009669:Nose Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D012878:Skin Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery
D000970:Antineoplastic Agents; D002945:Cisplatin
Cancer Radiother. 2009 Jan;13(1):47-54
18718802
Eur Arch Otorhinolaryngol. 2010 Apr;267(4):483-94
20052589
Head Neck. 2008 Dec;30(12):1559-65
18767173
Cell. 1990 Jan 12;60(1):167-76
2153055
Arch Dermatol. 1972 Jan;105(1):107-10
5009611
J Clin Oncol. 2000 Jun;18(12):2493-9
10856110
Am J Surg Pathol. 1992 Jun;16(6):584-92
1318003
J Invest Dermatol. 2009 Jan;129(1):9-11
19078983
Cancer. 1997 Sep 1;80(5):881-5
9307187
Eur J Cancer. 1996 Sep;32A(10):1734-8
8983282
Ear Nose Throat J. 2008 Nov;87(11):634-43
19006065
Int J Cancer. 2009 Sep 15;125(6):1243-9
19499546
Cell. 1979 May;17(1):43-52
222475
Int J Radiat Oncol Biol Phys. 1995 Jan 15;31(2):325-31
7836086
Nature. 1979 Mar 15;278(5701):261-3
218111
Science. 2008 Feb 22;319(5866):1096-100
18202256
Cancer Epidemiol Biomarkers Prev. 1999 Feb;8(2):153-8
10067813
J Surg Oncol. 2005 Jan 1;89(1):1-4
15611998
Proc Natl Acad Sci U S A. 2004 Jan 27;101(4):947-52
14732683
Cancer Invest. 2006 Dec;24(8):780-5
17162559
Cancer Res. 1993 Feb 1;53(3):523-7
8093854
J Invest Dermatol. 2007 Sep;127(9):2100-3
17700621
J Clin Oncol. 2002 Jan 15;20(2):588-98
11786590
Cancer. 1988 Aug 15;62(4):683-5
3293760
Cell Mol Life Sci. 2009 Jan;66(1):1-8
19023519
Arch Otolaryngol Head Neck Surg. 2001 Feb;127(2):149-54
11177031
J Am Acad Dermatol. 2008 Mar;58(3):375-81
18280333
J Clin Oncol. 2005 Apr 1;23(10):2300-9
15800320
Cancer Res. 2008 Jul 1;68(13):5009-13
18593898
Int J Radiat Oncol Biol Phys. 1995 Jan 15;31(2):315-23
7836085
ANZ J Surg. 2005 May;75(5):275-81
15932436
Onkologie. 2009 May;32(5):264-72
19420973